Market Place
Sourcing Support
Alumis & Acelyrin Announce Amended Merger Agreement
21 Apr 2025 //
GLOBENEWSWIRE
Alumis and Acelyrin File Proxy for Merger
04 Apr 2025 //
GLOBENEWSWIRE
Alumis and Kaken Pharma Collaborate on ESK-001 in Japan
25 Mar 2025 //
GLOBENEWSWIRE
Alumis Reports 2024 Financials, Highlights Recent Gains
19 Mar 2025 //
GLOBENEWSWIRE
Alumis to Present at Leerink`s 2025 Global Healthcare Conference
10 Mar 2025 //
GLOBENEWSWIRE
ESK-001 Ph2 OLE Data Shows 52-Week Psoriasis Response At AAD
08 Mar 2025 //
GLOBENEWSWIRE
Acelyrin Rejects Concentra’s Buyout Offer of Alumis Merger
06 Mar 2025 //
GLOBENEWSWIRE
Alumis To Present ESK-001 Ph 2 & Ph 3 Data At AAD 2025
28 Feb 2025 //
GLOBENEWSWIRE
Alumis Presents Ph 1 Data On A-005 TYK2 Inhibitor At ACTRIMS 2025
27 Feb 2025 //
GLOBENEWSWIRE
Alumis to Present at Oppenheimer 35th Annual Healthcare Conference
10 Feb 2025 //
GLOBENEWSWIRE
Acelyrin to be absorbed into Alumis in all-stock merger
08 Feb 2025 //
FIERCEBIOTECH
Alumis Strengthens Leadership Team with Key Appointments
28 Jan 2025 //
GLOBENEWSWIRE
Alumis Announces Positive Phase 1 Data for TYK2 Inhibitor A-005
19 Dec 2024 //
GLOBENEWSWIRE
Alumis Presents ESK-001’s Potential for Systemic Lupus
14 Nov 2024 //
GLOBENEWSWIRE
Alumis Reports Q3 2024 Results & Key Achievements
13 Nov 2024 //
GLOBENEWSWIRE
Alumis to Participate in Guggenheim Healthcare Innovation Conf
04 Nov 2024 //
GLOBENEWSWIRE
Late-Breaking Data Of ESK-001 For Psoriasis At EADV Demonstrate
27 Sep 2024 //
GLOBENEWSWIRE
Alumis to Participate in Upcoming September Investor Conferences
03 Sep 2024 //
GLOBENEWSWIRE
Alumis Reports Q2 2024 Results And Recent Achievements
13 Aug 2024 //
GLOBENEWSWIRE
Alumis Initiates Phase 3 Trial Of ESK-001 In Plaque Psoriasis
29 Jul 2024 //
GLOBENEWSWIRE
Therapy developer Alumis seeks up to $1 bln valuation in US IPO
29 Jun 2024 //
REUTERS
Therapy developer Alumis prices U.S. IPO at about $902M
28 Jun 2024 //
REUTERS
Alumis Announces Pricing of Initial Public Offering
27 Jun 2024 //
GLOBENEWSWIRE
Alumis Eyes IPO Over $300M To Fund TYK2 Pipeline
24 Jun 2024 //
FIERCE BIOTECH
Alumis plans IPO to fund TYK2 inhibitor through phase 3 trials
10 Jun 2024 //
FIERCE BIOTECH
Alumis: First Patient Dosed In Phase 1 Trial Of TYK2 Inhibitor A-005
30 Apr 2024 //
GLOBENEWSWIRE
Alumis to Participate in the 2024 Leerink Partners Global Biopharma Conference
11 Mar 2024 //
GLOBENEWSWIRE
Alumis Presents Positive Data from Phase 2 Clinical Trial of ESK-001
09 Mar 2024 //
GLOBENEWSWIRE
Alumis closes a $259M Series C to back its TYK2, flirts with talk about an IPO
06 Mar 2024 //
ENDPTS
Alumis Announces Upsized $259M Series C Financing
06 Mar 2024 //
GLOBENEWSWIRE
Alumis raises $259M in 2024`s largest biotech round so far
06 Mar 2024 //
FIERCE BIOTECH
Alumis Announces Late-Breaker Psoriasis Phase 2 Data Presentation for ESK-001
04 Mar 2024 //
GLOBENEWSWIRE
Alumis Presents Preclinical Data for Allosteric TYK2 Inhibitor A-005 at ACTRIMS
01 Mar 2024 //
GLOBENEWSWIRE
Alumis Announces Expansion of Allosteric TYK2 Inhibitor, ESK-001, Ph2 Program
29 Jun 2023 //
GLOBENEWSWIRE
Alumis Announces Initiation of Patient Dosing in Phase 2 Trial of ESK-001
28 Sep 2022 //
BUSINESSWIRE
Alumis Appoints Jörn Drappa as CMO and Roman G. Rubio as Senior Vice President
08 Sep 2022 //
BUSINESSWIRE
Alumis Expands Industry-Leading Leadership Team; Appoints General Counsel & CFO
06 Apr 2022 //
BUSINESSWIRE
Former Principia CEO Tapped to Lead Esker Therapeutics
24 Sep 2021 //
BIOSPACE
MyoKardia`s clinical ops lead jumps ship to Esker
20 Aug 2021 //
FIERCEBIOTECH
Esker Therapeutics Appoints Jeff Douglas as VP of Clinical Operations
19 Aug 2021 //
BUSINESSWIRE
Esker Therapeutics Appoints New Team Members and Board Director
21 Jul 2021 //
BUSINESSWIRE
Esker Therapeutics launches with $70M for autoimmune diseases
06 May 2021 //
FIERCEBIOTECH
Esker Therapeutics Launches to Transform the Treatment of Autoimmune Diseases
05 May 2021 //
BUSINESSWIRE
Esker, a new biotech startup, launches with plans to make targeted immune drugs
05 May 2021 //
BIOPHARMADIVE
